Equillium (EQ) vs Organigram Global (OGI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Equillium (EQ) has outperformed Organigram Global (OGI) over the past year, gaining 10.4% versus a loss of 60.6%. Over five years, EQ leads with a -80.4% price change compared with -93.3% for OGI. Equillium is the larger company by market cap ($87.3 million vs $82.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EQ | OGI |
|---|---|---|
| Share price | $1.06 | $0.583 |
| Market cap | $87.26M | $82.27M |
| 1-day change | -5.36% | -7.40% |
| YTD return | -31.61% | -65.30% |
| 1-year return | +10.42% | -60.61% |
| 5-year return | -80.41% | -93.25% |
| P/E ratio (TTM) | — | 1.36 |
| Forward P/E | — | 27.76 |
| EPS (TTM) | $-0.12 | $0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-22.40M | — |
| 52-week high | $3.54 | $2.24 |
| 52-week low | $0.81 | $0.583 |
| Distance from 52-week high | -70.06% | -73.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +707.55% | — |
| Average volume | 544.39K | 567.77K |
| Shares outstanding | 82.32M | 141.11M |
| Employees | 14 | 1,139 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EQ has outperformed OGI by 71.0 percentage points over the past year.
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
EQ vs OGI FAQ
Which is bigger, Equillium or Organigram Global?
Equillium (EQ) is larger, with a market capitalization of $87.26M compared with $82.27M for Organigram Global (OGI).
Which stock has performed better over the past year, EQ or OGI?
EQ returned +10.42% over the past 12 months, compared with -60.61% for OGI (price return, excluding dividends). Past performance does not predict future results.
Are Equillium and Organigram Global in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.